July 10, 2017
BioInvent and ThromboGenics amending long-standing monoclonal antibody development agreement
BioInvent International and ThromboGenics have agreed to amend their long-standing agreement, which covers the co-development of the novel anti-PlGF monoclonal antibody products TB-403 and THR-317.